Memorial Sloan Kettering Cancer Center

Massachusetts Institute of Technology

Sarah M Cheal

Steven M Larson

Nai-Kong V Cheung

Karl Dane Wittrup

Ouathek Ouerfelli

Hong Xu

Guangbin Yang

Alice Tzeng

Michael R McDevitt

Steve Larson

David Ulmert

Joseph Reginald Osborne

Pat B Zanzonico

Edward Komin Fung

Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof

The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g.,Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy

The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.

N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy

The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.

Systems and methods for determining optimum patient-specific antibody dose for tumor targeting

Growing community of inventors

New York, NY, United States of America

Sarah M Cheal